Piper Sandler reiterated coverage on Seagen with a new price target
$SGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Piper Sandler reiterated coverage of Seagen with a rating of Neutral and set a new price target of $150.00 from $165.00 previously